Cite
MLA Citation
D Faleck et al.. “DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn's disease but not ulcerative colitis: a multi-centre consortium analysis.” Journal of Crohn's and colitis, vol. 12, n.d., p. S066. http://access.bl.uk/ark:/81055/vdc_100095512897.0x000011